Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

Viruses

Samantha Turnbull²  Emma J. West²  Karen J. Scott²  Elizabeth Appleton²  Alan Melcher²  Christy Ralph¹  Martine Lamfers² 

[1] Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS2 9JT, UK

关键词: oncolytic virus;    immunotherapy;    reovirus;    vaccinia;    HSV;    clinical trials;   

DOI  :  10.3390/v7122938

来源: mdpi

【 摘 要 】

The last few years have seen an increased interest in immunotherapy in the treatment of malignant disease. In particular, there has been significant enthusiasm for oncolytic virotherapy, with a large amount of pre-clinical data showing promise in animal models in a wide range of tumour types. How do we move forward into the clinical setting and translate something which has such potential into meaningful clinical outcomes? Here, we review how the field of oncolytic virotherapy has developed thus far and what the future may hold.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.